AbbVie rose 2.9% over the past five trading days even as the S&P 500 fell 1.0%, standing out as a rare gainer in a weaker market.
A 0.23 five-year correlation with the S&P 500 suggests most of AbbVie’s returns have come from company-specific drivers rather than broad market moves.
Over the past year, AbbVie captured only 16% of the market’s up days but tended to rise by about 32% of the market’s losses on down days, giving it a hedge-like profile.
Recent business momentum has supported that pattern: AbbVie posted 12.4% revenue growth to $15 billion, lifted by 29% Skyrizi sales growth and 20% Rinvoq growth, and raised full-year earnings guidance.
Pipeline wins including positive Phase 3 Epcoritamab data and a new pediatric FDA approval for Skyrizi add support, though investors are watching whether AbbVie can defend immunology market share as competition intensifies.